CDXS vs RVTY vs DHR Stock Comparison

Codexis, Revvity and Danaher Prices as of Nov 3, 2026 Peers: Industry group
1 more company in this comparison (BRKR) Create a free account to keep reading and compare up to 10 companies.
CDXS Codexis, Inc.
$1.08 -20.6% 1M -52.2% 1Y
Market cap
$97.88M
P/E
–
Revenue (TTM)
$77.68M
Div. yield
–
Life Sciences Tools Healthcare
2 wins
RVTY Revvity, Inc.
$163.63 +8.0% 1M +76.0% 1Y
Market cap
$17.93B
P/E
75.5x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare
2 wins
DHR Danaher Corp /De/
$230.08 +7.5% 1M +7.5% 1Y
Market cap
$165.27B
P/E
38.2x
Revenue (TTM)
$25.61B
Div. yield
–
Life Sciences Tools Healthcare
7 wins

Head to Head

11 decided of 12

Danaher leads on 7 of the 12 questions below (Danaher 7, Codexis 2, Revvity 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCDXSRVTYDHRLeader
Larger companyMarket capitalisation $97.88M $17.93B $165.27B DHR
Cheaper on earningsLower P/E, profitable companies only -3.2x 75.5x 38.2x DHR
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 32.1x 25.3x DHR
Faster revenue growthRevenue growth, trailing twelve months +35.9% +4.1% +5.5% CDXS
More profitableNet margin, trailing twelve months -39.6% 8.2% 16.9% DHR
Better return on capitalReturn on invested capital -35.1% 3.1% 5.8% DHR
Less leveragedLower net debt / EBITDA 0.7x 2.8x 2.6x CDXS
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months -52.2% +76.0% +7.5% RVTY
Better 5-year returnAnnualised price return, 5 years -50.1%/yr -1.0%/yr -5.5%/yr RVTY
Less volatileAnnualised volatility, 1 year 87.6% 40.7% 30.7% DHR
Higher overall scoreMean of the five percentile scores vs peers 45/100 57/100 60/100 DHR

Percentile Scorecard

CDXSRVTYDHR

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCDXSRVTYDHR
Valuation 41 #135 of 229 68 #73 of 229 71 #67 of 229
Growth 67 #73 of 221 28 #160 of 221 26 #163 of 221
Profitability 43 #120 of 209 80 #43 of 209 86 #30 of 209
Financial Health 30 #168 of 240 48 #126 of 240 47 #127 of 240
Shareholder Returns 43 #85 of 147 63 #55 of 147 71 #43 of 147
Overall 45 57 60
  • CDXS ranked among 248 companies in Medical Devices and Diagnostics
  • RVTY ranked among 248 companies in Medical Devices and Diagnostics
  • DHR ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCDXSRVTYDHRSPY
1 month -20.6%+8.0%+7.5% -2.0%
3 months -24.5%+47.1%+18.1% -2.2%
6 months -60.7%+77.3%+31.8% +4.2%
Year to date -33.7%+69.1%+0.5% +10.6%
1 year -52.2%+76.0%+7.5% +10.4%
3 years -44.0%+85.6%+16.3% +73.6%
3 years, per year -17.6%+22.9%+5.2% +20.2%
5 years -96.9%-4.9%-24.8% +61.6%
5 years, per year -50.1%-1.0%-5.5% +10.1%
10 years -75.5%+226.2%+200.6% +261.3%
10 years, per year -13.1%+12.6%+11.6% +13.7%

Risk

MeasureCDXSRVTYDHRSPY
Volatility, 1Y 87.6%40.7%30.7% 12.8%
Downside volatility, 1Y 92.7%36.6%31.8% 12.8%
Beta vs S&P 500, 1Y 1.881.260.48 1.00
Return / volatility, 1Y -0.601.870.24 0.81
Max drawdown, 5Y -97.7%-59.2%-50.8% -25.4%
From 52-week high -62.1%-1.3%-4.9% -3.2%
52-week high $2.85$165.78$242.05 $779.14
52-week low $0.98$82.26$161.91 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCDXSRVTYDHR
P/E now vs peer median -3.2xmedian 28.1x 76.9xmedian 28.1x 37.4xmedian 28.1x
P/S now vs peer median 1.3xmedian 2.9x 6.3xmedian 2.9x 6.3xmedian 2.9x
EV/EBITDA now vs peer median -4.0xmedian 18.0x 26.3xmedian 18.0x 23.3xmedian 18.0x
P/FCF now vs peer median -8.1xmedian 24.8x 32.1xmedian 24.8x 28.3xmedian 24.8x
P/B now vs peer median 3.0xmedian 2.3x 2.5xmedian 2.3x 3.0xmedian 2.3x
PEG now vs peer median -0.12median 0.95 -2.47median 0.95 -4.66median 0.95

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCDXSRVTYDHR
Revenue $77.68M $2.91B $25.61B
Gross profit $67.60M $1.60B $15.01B
Operating income -$27.66M $358.85M $5.22B
Net income -$30.72M $237.55M $4.33B
Free cash flow -$12.18M $568.85M $5.73B
R&D $48.74M $215.83M $1.67B
EPS (diluted) $-0.34 $2.13 $6.13
Cash & equivalents $27.17M $1.02B $5.68B
Total debt $40.88M $3.21B $26.48B
Shares (diluted) 91.05M 111.63M 706.80M
Enterprise value -$159.17M $14.20B $144.92B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCDXSRVTYDHR
P/E -3.2x 76.9x 37.4x
P/FCF -8.1x 32.1x 28.3x
P/Operating cash flow -9.5x 28.6x 23.6x
P/S 1.3x 6.3x 6.3x
P/B 3.0x 2.5x 3.0x
P/Tangible book 3.0x 3.6x 5.0x
EV/EBITDA -4.0x 26.3x 23.3x
EV/EBIT -3.1x 57.0x 35.0x
EV/Revenue 1.1x 7.0x 7.1x
EV/FCF -7.0x 35.9x 31.9x
EV/Operating cash flow -8.1x 32.0x 26.6x
PEG (3Y EPS CAGR) -0.12 -2.47 -4.66

Growth

14 metrics
MetricCDXSRVTYDHR
Revenue growth (1Y) 35.9% 4.1% 5.5%
Revenue CAGR (3Y) -7.8% 0.9% 1.3%
Gross profit growth (1Y) 52.4% 2.3% 3.9%
Gross profit CAGR (3Y) -2.6% -0.4% 1.2%
Operating income growth (1Y) 51.7% -5.5% 13.1%
Operating income CAGR (3Y) 22.8% -3.7% -3.8%
Net income growth (1Y) 52.7% -16.7% 23.6%
Net income CAGR (3Y) 18.5% -33.8% -9.9%
EPS growth (1Y) 55.7% -12.3% 24.8%
EPS CAGR (3Y) 26.2% -31.2% -8.0%
Operating cash flow growth (1Y) 83.0% 6.2% 8.6%
Operating cash flow CAGR (3Y) -152.3% 86.9% -5.3%
Free cash flow growth (1Y) 82.0% 9.5% 14.2%
Free cash flow CAGR (3Y) -26.3% 64.8% -5.8%

Profitability

14 metrics
MetricCDXSRVTYDHR
Gross margin 87.0% 55.0% 58.6%
EBITDA margin -27.0% 26.6% 30.7%
Operating margin -35.6% 12.3% 20.4%
Pretax margin -39.5% 9.0% 18.8%
Net margin -39.6% 8.2% 16.9%
FCF margin -15.7% 19.5% 22.4%
Operating cash flow margin -13.4% 21.9% 26.8%
Return on equity -80.6% 3.3% 8.2%
Return on assets -24.6% 2.0% 4.7%
Return on invested capital -35.1% 3.1% 5.8%
Return on capital employed -27.3% 3.3% 6.2%
Asset turnover 0.6x 0.2x 0.3x
Cash conversion (OCF / net income) 0.3x 2.7x 1.6x
Stock comp / revenue 9.9% 0.8% 1.3%

Financial Health

11 metrics
MetricCDXSRVTYDHR
Debt / assets 34.0% 26.6% 28.4%
Debt / equity 1.2x 0.4x 0.5x
Net debt / EBITDA 0.7x 2.8x 2.6x
Debt / FCF -3.4x 5.6x 4.6x
Liabilities / assets 72.5% 40.0% 42.5%
Equity / assets 27.5% 60.0% 57.5%
Interest coverage – 3.7x 14.5x
Current ratio 3.1x 1.8x 1.6x
Quick ratio 2.9x 1.4x 1.1x
Cash ratio 2.3x 0.8x 0.6x
Altman Z-score -6.27 3.43 3.72

Shareholder Returns

7 metrics
MetricCDXSRVTYDHR
Dividend yield – 0.2% 0.7%
Net buyback yield -0.3% 2.6% 0.6%
Shareholder yield -0.3% 2.7% 1.2%
Payout ratio (earnings) – 13.4% –
Payout ratio (FCF) – 5.6% –
Dividend growth (1Y) – -6.3% –
Dividend CAGR (3Y) – -6.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCDXSRVTYDHR
Forward P/E – 32.1xFY2026 25.3xFY2026
EPS, next fiscal year $-0.37FY2026 $5.10FY2026 $9.11FY2026
EPS growth, next FY – +0.8%FY2026 +16.8%FY2026
EPS growth, the year after – +11.0% +8.0%
Revenue, next fiscal year $77.93MFY2026 $2.98BFY2026 $27.01BFY2026
Revenue growth, next FY +10.7%FY2026 +4.0%FY2026 +9.9%FY2026
Revenue growth, the year after +9.2% -2.0% -1.9%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCDXSRVTYDHR
Held by institutions 71.0% 100.0% 81.9%
Institutions holding 148 547 2,120
Change in shares held, QoQ -2.4% -1.3% +1.1%
Institutions buying 88 303 842
Institutions selling 36 161 1,015
Buyers to sellers 2.44 1.88 0.83

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CDXSRVTYDHR
CDXS 1.00 0.11 0.07
RVTY 0.11 1.00 0.52
DHR 0.07 0.52 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CDXS, RVTY and DHR?

Danaher (DHR) is the largest by market capitalisation: Codexis (CDXS) $97.88M, Revvity (RVTY) $17.93B, Danaher (DHR) $165.27B.

Which stock is cheaper, CDXS, RVTY and DHR?

Danaher (DHR) trades on the lowest price-to-earnings ratio (Codexis (CDXS) -3.2x, Revvity (RVTY) 75.5x, Danaher (DHR) 38.2x). On next year's consensus earnings, Danaher (DHR) is cheapest (Revvity (RVTY) 32.1x, Danaher (DHR) 25.3x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Codexis (CDXS) grew revenue fastest over the trailing twelve months: Codexis (CDXS) +35.9%, Revvity (RVTY) +4.1%, Danaher (DHR) +5.5%.

Which company is more profitable?

Danaher (DHR) has the highest net margin (Codexis (CDXS) -39.6%, Revvity (RVTY) 8.2%, Danaher (DHR) 16.9%). On return on invested capital, Danaher (DHR) leads (Codexis (CDXS) -35.1%, Revvity (RVTY) 3.1%, Danaher (DHR) 5.8%).

Which stock has performed better?

Over the past year Revvity (RVTY) returned the most: Codexis (CDXS) -52.2%, Revvity (RVTY) +76.0%, Danaher (DHR) +7.5%. Over five years, Revvity (RVTY) compounded fastest (Codexis (CDXS) -50.1%/yr, Revvity (RVTY) -1.0%/yr, Danaher (DHR) -5.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Codexis (CDXS) 0.00%, Revvity (RVTY) 0.00%, Danaher (DHR) 0.00%. Codexis (CDXS) and Danaher (DHR) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Codexis (CDXS) 87.6%, Revvity (RVTY) 40.7%, Danaher (DHR) 30.7%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CDXS, RVTY and DHR?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Danaher (DHR) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.